SUMMARY
We present the clinical data and subthalamic recordings of a patient with Parkinson’s disease treated for one year with adaptive deep brain stimulation (aDBS). This novel stimulation mode, which adjusts the current amplitude linearly with respect to subthalamic beta power, produced a clinical benefit that was superior to the previous conventional stimulation that used constant, predefined parameters (cDBS). Compared with cDBS, the subthalamic beta amplitude was higher with aDBS and displayed larger daily fluctuations. Furthermore, subthalamic beta amplitude decreased during sleeping with respect to waking hours under aDBS. These data suggest a robust neuromodulatory mechanism of aDBS, with a clinical effect that was superior in this patient compared to cDBS. Our results open new perspectives for a restorative brain network effect of aDBS as a more physiologic, bidirectional, brain–computer interface.
Competing Interest Statement
VA, MA, and LR are employees and shareholders of Newronika S.p.A. IUI is a Newronika S.p.A. consultant and shareholder. SM and AP are founders and shareholders of Newronika S.p.A. IUI and RE received funding for research activities from Newronika S.p.A. IUI is Adjunct Professor at the Department of Neurology, NYU Grossman School of Medicine.
Clinical Trial
NCT04681534
Funding Statement
This study was funded by the European Union - Next Generation EU - NRRP M6C2 - Investment 2.1 Enhancement and strengthening of biomedical research in the NHS, and by the Fondazione Grigioni per il Morbo di Parkinson. IUI and CP were supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Project-ID 424778381 - TRR 295. IUI was supported by a grant from the New York University School of Medicine and The Marlene and Paolo Fresco Institute for Parkinson's and Movement Disorders, which was made possible with support from Marlene and Paolo Fresco.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Fondazione IRCCS Istituto Neurologico Carlo Besta gave ethical approval for this work (protocol NWK_AlphaDBS_FIM_2019).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵11 Lead contact
Data Availability
All data produced in the present study are available upon reasonable request to the authors
